Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Premium RA Capital Preps New Biotech SPAC — With an Eye on China’s Risks Stephen Taub Premium Coatue’s Unicorn Spree Marks Its Busiest VC Quarter in Nearly Four Years Stephen Taub Podcast- Commercial Mortgage-backed Securities: The Crossroads of Real Estate Debt and Liquid Credit Sponsored by Fidelity Investments